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Summary
Background. Bisphosphonates are drugs which act on bone
metabolism. They act on osteoclastic activity and inhibit
neoangiogenesis. In the bisphosphonate class the most clini-
cally used molecules are pamidronate and zolendronate. They
represent “the gold standard” and are used in multiple myelo-
ma treatment, solid tumors with bone metastases, and preven-
tion of pathological fractures.
In recent years it has been supposed that bisphosphonates
may lead to jaws osteonecrosis, expecially after dentistry pro-
cedures such as dental extractions, implant surgery and peri-
odontics interventions.
Our work aim is to delineate clinical aspects of patients’ le-
sions come to our observation for jaws osteonecrosis. These
belonged to a patients’ group treated by bisphosphonates for
multiple myeloma, osteoporosis, hyperparathyroidism, Paget’s
disease.
Patients and methods. We examinated clinical data of 9 pa-
tients (8 females, 1 male), with jaws osteonecrotic lesions and
treated by bisphosphonates, for a mean time of 42 months.
Six of the 9 patients were treated for multiple myeloma. In 4
cases osteonecrotic were located on superior maxillary, in 5
ones on jaw. Clinically exposed bone area was infected, with
radiated and burning pain, and antibiotic therapy was neces-
sary.
Results. Most clinically represented lesion was an area of ul-
cerated mucosa with not vital exposed bone. Flogosis was typ-
ical in area surrounding the necrosis. Neither bleeding nor
pain could be appreciated in the exposed bone area. Painful le-
sions make more difficult oral hygiene, with frequent onset of
local parodontosis. At radiographic exams typical illness
marks are not corresponded instead. A standardized protocol
for jaws osteonecrosis doesn’t exist. In our clinical trial we per-
formed several clinical plans, with different results. The sus-
pension of bisphosphonate therapy does not appear to hasten
recovery of the osteonecrosis. Despite antibiotic therapy, re-
sective surgery, osteoplastics and hyperbaric oxygen therapy
most of the lesions did not respond well to therapy.
Discussion. Although bisphosponates use started about 30
years ago, first osteonecrotic lesions were described in 2003
(Max and Stern). The pathogenesis is correlated to the modifi-
cations of vascularization induced from such drugs, but
would compete even factors as masticatory stress, iatrogenic
procedures, local bacterial position, association with other
drugs and some systemic pathologies. Surgical treatment
may lead to not predictable results and recurrences. Antibiotic
therapy reduces the inflammation and the pain, but did not as-
sure healing; therapies with disinfectant and irrigantes have
not produced results; in our clinic the hyperbaric oxygen thera-
py has gotten good results toward in the comparisons of the
inflammation and in the improvement of the course-operating
after sequestrotomy.
Conclusions. Bisphosphonates are essential drugs in the
treatment of several diseases other than osteoporosis. But
considering the impact on the quality of life of the patients on
which rise up osteonecrosis of the maxillary, it is necessary to
perform odontostomatologic visit before the therapy, and to
evaluated the relationship between benefit of the treatment
and the risk of such lesions.
KEY WORDS: osteonecrosis, bisphosphonates, osteoporosis, multiple
myeloma.
Introduction
Bisphosphonates are non-metabolised pyrophosphonates ana-
logues that are absorbed on the durapatite crystals of the bone
matrix slowing down both growth speed and break-up by
strongly inhibiting osteoclast activity (1). 
Their clinical use dates back to 30 years ago (2), and in the
years they have been mainly used in onco-haematology for the
treatment of patients suffering from severe malignancies with
bone metastasis such as lung, breast and prostate cancer, in
hypercalcemia of malignancy, in the treatment of multiple
myeloma and they are also prescribed in the osteoporosis and
Paget’s disease (3-6).
Several bisphosphonate molecules are on the market but the
most widely used in the clinical setting are pamidronate and
zolendronate (7).
Bisphosphonates act on osteoclasts blocking their function in
several ways: inhibiting the osteoclast formation from mono-
cytes (8), reducing the osteoclasts’ life cycle (9), inhibiting os-
teoclastic activity on the bone surface (10).
At a molecular level, bisphosphonates are deemed to modulate
osteoclast function interacting with a surface cell receptor or
with an intracellular enzyme (11). Considering that they are not
metabolised and have a strong binding affinity with osteoclasts,
they produce their death (osteoclasts apoptosis) (12).
In addition to the anti-reabsorption effect on the bone, an anti-
angiogenetic effect on animals has been recently described
(13). Bisphosphonates can inhibit the endothelial cell function
both in vivo and in vitro (14). The cells treated with bisphos-
phonates have shown a decreased proliferation, an increased
apoptosis and a reduced capillary vessels formation (15, 16).
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As to negative side effects, treatment with bisphosphonates
produced flu-like symptoms, fatigue, gastrointestinal disorders,
anaemia, dyspnoea and oedemas (7). Oral and oesophageal
mucosal ulcerations were also observed (7, 17, 18).
In 2003, following the clinical observations by Marx and Stern
(19) in patients suffering from myeloma, a possible implication
of bisphosphonates in the development of maxillary osteonecro-
sis was postulated. Afterwards, this hypothesis was also sup-
ported by several Authors who highlighted a strong correlation
between intra-oral bone necrosis and bisphosphonates treat-
ment, in particular after tooth avulsion or other oral cavity surgery
(20-23).
Hence, the aim of this article is to describe the clinical aspects
of the osteo-necrotic lesions in a group of patients suffering
from myeloma and treated with bisphosphonates. Furthermore,
the possible pathogenetic mechanisms will be also dealt with
because the authors are convinced that these lesions are a
possible complication of bisphosphonates treatment.
Patients and methods
We analysed the clinical data of 9 patients demanding treat-
ment for maxillary bone necrosis of unknown origin, sent to us
by the Haematology department of the “San Giacomo” Hospital
of Rome. The 9 patients belong to a group of 54 patients (41F,
13M) who were under bisphosphonate treatment for multiple
myeloma, osteoporosis, hyperparathyroidism and Paget’s dis-
ease (Table I).
Table I - Group of analysed patients.
Diagnosis Patient’s number
Asymptomatic myeloma 14 (3F, 1M)
Symptomatic myeloma 36 (28F, 8M)
Osteoporosis 18 (6F, 2M)
Hyperparathyroidism 14 (4F)
Paget’s disease 12 (2M)
Total 54 (41F, 13M)
Table II shows the clinical data of the 9 patients with maxil-
lary osteonecrosis associated with bisphosphonate treat-
ment. The group included 8 females and 1 male, with aver-
age age 71 years (range 89-59) and affected for multiple
myeloma (6 cases), chronic leukemia (1 case), osteoporosis
(1 case) and Waldenstrom’s disease with osteoporosis (1
case). Average bisphosphonates treatment duration was 42
months (range 18-75). Oral manifestations were of upper
maxillary osteonecrosis areas in 4 cases and mandibular le-
sions in 5 cases. All patients were under observation be-
cause of the presence of an infection in the exposed areas,
with stinging and diffused pain that demanded systemic an-
tibiotic treatment. 
Table II - Demographics of 9 patients with bisphosphonates-associated oral cavity osteonecrosis.
Patient Sex Age Systemic disease Bisphosphonates Oral manifestations Therapy
n. therapy (type/location)
(months)
1 F 81 Multiple myeloma-k Pamidronate (2) Osteonecrosis, infection/ Antibiotics, Rinses, 
Zolendronate (27) mandible postextraction Analgesics
2 F 58 Waldenstrom’s disease Pamidronate (59) Osteonecrosis, infection/ Sequestrectomy,
and severe osteoporosis Zolendronate (27) maxilla Hyperbaric oxigen therapy,
Antibiotics
3 M 84 Multiple myeloma IgG-lamba Zolendronate (18) Osteonecrosis, infection/ Sequestrectomy,
maxilla postextraction Antibiotics
4 F 59 Multiple myeloma IgA-k Pamidronate (75) Osteonecrosis, infection/ Sequestrectomy,
mandible postextraction Hyperbaric oxigen therapy,
Antibiotics
5 F 67 Multiple myeloma IgG-k Pamidronate (13) Osteonecrosis, infection/ Sequestrectomy,
Zolendronate (34) mandible postextraction Hyperbaric oxigen therapy,
Antibiotics
6 F 70 Multiple myeloma IgG-k Pamidronate (53) Osteonecrosis, infection/ Antibiotics, Rinses
Zolendronate (27) maxilla
7 F 72 Severe osteoporosis with Pamidronate (26) Osteonecrosis, infection/ Sequestrectomy,
chronic lymphatic leukemia Zolendronate (20) mandible postextraction Hyperbaric oxigen therapy,
Antibiotics
8 F 71 Severe osteoporosis Pamidronate (3) Osteonecrosis/mandible Antibiotics, Rinses
Zolendronate (47)
9 F 78 Multiple myeloma IgG-k Pamidronate (20) Osteonecrosis, infection/ Hyperbaric oxigen therapy,
Zolendronate (29) maxilla Antibiotics
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Results
Clinical aspects
The most common clinical aspect of the lesions was mucosal
ulceration with a non-vital bone exposure (Figs. 1, 2 and 3).
In 1 case, we observed a mucosal fistula with a mild serosan-
guineous exudation. The exposed bone was yellowish/whitish
whereas the surrounding mucosa was often irritated and
painful if touched (Fig. 4). On the other hand, the exposed
bone did not cause any pain and did not bleed. The clinical
situation showed all the features of avascular bone necrosis.
Bone lesions showed a quite regular surface that in the fol-
lowing became irregular as a consequence of bone micro-
traumatisms during chewing. In 1 case, the above mentioned
irregularity produced ulcerations of the tongue edge touching
the bone surface (Fig. 5). In 4 cases, bone exposed areas in-
volved the upper maxillary at the crest and on the palate and
in 5 cases the mandible on the postero-lingual and crest ar-
eas. When bone necrosis was close to the teeth, a deteriora-
tion of the local hygiene conditions was observed, with initial
damage to the soft tissue with subsequent increased tooth
mobility and loss. Case history revealed a previous interven-
tion of the oral cavity, in particular tooth avulsions, insertion
or removal of implants with subsequent incomplete healing
of the surgical site and osteonecrosis of the post-avulsion
Figure 5 - Exposed necrotic bone on the posterior left lingual side of the
Figure 1 - Exposed necrotic alveolar bone after tooth 31 extraction. Figure 4 - Bone necrosis and secondary infection near palatal root of
tooth 26.
Figure 3 - Nonhealing alveolus with bone necrosis after the extraction
of tooth 15.
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fault.
Depending of the clinical situation of osteonecrosis, radi-
ographic evaluation and computerized tomography did not
show any radiographic signs of the disease (Figs. 6, 7).
The absence of the radiographic signs of the disease was
probably due to the early development of the lesions contrarily
to osteomyelitis where an active bone resorption or sequestra-
tion were observed.
Treatment
Treatment of patients with bisphosphonates-associated os-
teonecrosis was difficult and was based on the different clinical
situations. Even tough we do not have any scientific data to sup-
port a protocol for the treatment of patients with osteonecrosis
treated with bisphosphonates, we are following the recommen-
dations issued by the Expert Committee in June 2004 (24). Our
study showed a high variability of responses. Despite discontinu-
ation of bisphosphonate treatment at the osteonecrosis diagno-
sis, none patient showed any improvement.
The most common therapeutical approach consisted in the ad-
ministration of systemic antibiotics (metronidazole 250x3 mg
and moxifloxacine 400 mg/die) combined to a local clorexidine
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Table III - Disease and events associated with osteonecrosis (any
bone).
Disease or etiologic factor Subcategories
Alcohol abuse Cirrhosis; Pancreatitis
Arthritis Subchondral cyst; Subchondral marrow
edema
Atmospheric pressure Caisson’s disease; Deep-sea divers
variations disease
Blood dyscrasias Disseminated intravascular coagulation
(DIC); Leukemia; Sickle cell anemia
Cancer Chemotherapy for cancer; Cancer-
induced hypercoagulation; Lymphoma;
Metastatic intraosseus carcinoma;
Radiation therapy for cancer
Chronic inactivity Bedridden; Full body cast; Paraplegic
Corticosteroids Hypercortisolism; Inflammatory bowel
disease; Lupus erythematosus;
Transplants
Estrogen Birth control pills; Estrogen replacement
therapy; Fertility drugs; Pregnancy;
Prostate chemotherapy; Transient
ischemic osteoporosis
Gaucher’s disease
Hemodialysis
Hypercoagulable state, Acute infection/inflammation; Chronic
local infection/inflammation; Increased 
intramedullary pressures
Hypercoagulability Antiphospholipid antibody syndrome; 
Factor V gene mutation
hyperhomocysteinemia; Homozygosity
for MTHFR or CBS*; Protein C
deficiency; Protein S deficiency
Hyperlipidemia & Diabetes mellitus; Dysbaric 
embolic fat phenomena; Fracture of bone;
Hemoglobinopathies; Osteomyelitis
acute
Hypertension
Hypothyroidism
Inflammation intraosseous Bacterial and viral infection; Trauma
(mild or severe); Autoimmunity/
hypersensitivity
Hypersensitivity reactions Allograft organ rejection; Anaphylactic
shock; Immunoglobulin therapy
Lupus erythematosus With corticosteroid therapy; Without
corticosteroid therapy
Neurodamage Brain injury/surgery
Osteoporosis Regional or generalized
Starvation Anorexia nervosa
Storage diseases Gaucher’s disease
Tobacco use Tobacco smoking
Vascular occlusive disease Atherosclerosis
Vasculitis
Vasoconstriction Local anestesia (with vasoconstrictor);
Raynaud’s phenomenon; Tobacco use
* MTHFR: methylene tetrahydrofolate reductase; CBS: cystathionine beta-
synthetase.
Figure 6 - Radiographic view of the area of tooth 31 without sequestra-
Figure 7 - Panoramic radiograph of the mandible following extraction of
tooth 46. The image shows the mottled bone in the not healing extrac-
tion sites.
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therapy followed by surgical toilette of the necrotic area or re-
moval of the bone sequestrum.
Aggressive bone surgery was performed on three patients to
remove necrotic bone tissue and to enhance healing starting
from the vital bone edges.
Nevertheless in one patient produced a deterioration of the
bone damage with deepening of the necrosis and clinical ag-
gravation (Fig. 8).
Hence, patients should be informed as to the risks of surgery
and of the possible complications implying a deterioration of
the lesions.
In the other cases, osteoplasty produced an improvement con-
sisting mainly of the decrease of adverse effects of the mucos-
al traumatisms.
Hyperbaric oxygen therapy (thirty sessions) performed on 4 pa-
tients produced a clinical improvement of lesion infection and a
reduction of lesion-related pain but did not produce a restitutio
ad integrum. 
Discussion
The observation of the clinical cases described above could
suggest that the origin of osteonecrosis has to be associated to
pamidronate and zolendronate-induced insufficient vascularity.
Hence, the onset of the lesions could be considered as a com-
plication of bisphosphonate treatment as it has been shown by
the literature (20-23).
In 2003 Marx and Stern (19) were the first to describe os-
teonecrosis in patients suffering from multiple myeloma and
treated with bisphosphonates, even though this medication had
been used for more than thirty years. 
No osteonecrotic lesions had been observed in the clinical tri-
als for these drugs and this leads us to infer that other factors
could contribute to the onset of lesions. The selective onset of
maxillary lesions could be associated with an ecosystem of the
oral cavity that can highly colonize any open wound (post-avul-
sion sites).
Maxillary osteonecrosis is probably due to the inability of an
hypodynamic and hypovascular bone to support an increased
healing demand with bone remodelling following physiological
distress (chewing), iatrogenic traumas (tooth avulsions, implant
surgery, periodontal operations) and tooth infections in an envi-
ronment such as the oral cavity that is continuously exposed to
traumas and to a strong bacterial action. Other factors could be
concomitant medications with anti-angiogenic properties (such
as glucocorticoids, talidomide, chemotherapeutic drugs), dia-
betes mellitus, maxillary irradiation, peripheral vascular disor-
ders and clinical conditions associated with the development of
osteonecrosis in any points (25).
The management of patients with bisphosphonate-associated
maxillary osteonecrosis is particularly complicated. The surgi-
cal ablation of the necrotic bone cannot fully control the dis-
ease because of the difficulties in obtaining surgical edges with
a vascularised bone or because of relapses that could expose
an even larger osteonecrotic area. For this reason, resection
surgery should be performed on symptomatic patients only.
Antibiotics treatment administered to control the infections in
exposed areas gives positive results reducing tissue inflamma-
tion and relieving pain. However, antibiotics cannot lead to a
complete healing of lesions. Topic treatment with disinfectant-
based mouth wash has not shown any efficacy. In our experi-
ence, hyperbaric oxygen therapy seems to give positive results
on controlling inflammation of exposed areas and on improving
the post-surgery course in patients that have undergone se-
questrotomy. None of the treated patients has shown a dehis-
cence of surgical wounds. 
Today, bisphosphonates are the standard treatment for pa-
tients suffering from multiple myeloma and neoplasia with bone
metastasis and they give excellent results in preventing patho-
logic bone fractures. Nevertheless, the onset of the abovemen-
tioned complications produced a deterioration of the quality of
life and led to discontinuation of treatment. Furthermore, bis-
phosphonates are used for treating osteoporosis: hence their
use must be carefully monitored. In most cases, the diagnosis
is made by the oral surgeon because the oncologist often un-
derestimates or misunderstands this complication. Hence, the
medical community as a whole should become fully aware of
this risk.
Conclusions
So, likewise the patients demanding radiation therapy for the
heads and the neck, all patients eligible for bisphosphonate
treatment should undergo a dental check up in order to detect
any possible dental condition before starting therapy. As for the
patients already treated, we strongly recommend dentists to
collect an accurate anamnesis in order to single out not only
pre-existent conditions but also the type of treatment that the
patient has followed before performing any kind of oral surgery.
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